The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Sets Stricter Requirements for Immediate-Release Opioids to Prevent Misuse & Abuse

FDA Sets Stricter Requirements for Immediate-Release Opioids to Prevent Misuse & Abuse

October 27, 2017 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

“Many people who are currently addicted to opioids became medically addicted,” says U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD. Dr. Gottlieb also says that approximately 90% of all opioids prescribed are for immediate-release (IR) formulations, which account for approximately 160 million yearly prescriptions.1 Because of this, the FDA is expanding its Risk Evaluation and Mitigation Strategy (REMS) program to include manufacturers of IR opioids.

You Might Also Like
  • FDA Expands Safety Measures for Immediate Release Opioids
  • Makers of Fast-Acting Opioids Will Have to Pay for Training—FDA
  • FDA Panel Backs Teva’s Abuse-Resistant Opioid Painkiller
Also By This Author
  • Clinical Trials: Zilretta Promising for Knee OA Pain & Golimumab Completes Phase 3 Trial

Since 2012, 64 extended-release (ER)/long-acting (LA) opioid products have been subject to the FDA’s REMS program. Manufacturers of these ER/LA opioids must provide training on safe prescribing practices, the consideration of non-opioid pain medications or other subjects to prescribers. To meet this requirement, ER/LA opioid analgesic manufacturers have been providing unrestricted grants to accredited continuing medical education providers to develop courses based on content outlined by the FDA, which the agency calls the blueprint.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The FDA recently sent letters to 74 manufacturers of IR opioids intended for use in the outpatient setting, notifying them that IR opioids will be subject to REMS following a public comment period. Along with the makers of ER/LA opioids, IR opioid manufacturers will soon be required to provide training and fund the development of education courses for doctors, nurses, pharmacists and other healthcare professionals involved in managing pain patients (e.g., those who prescribe, treat and monitor pain patients).

Dr. Gottlieb says the FDA believes all healthcare professionals involved in patient pain management must be educated about the safe use of opioids to ensure these products are actually indicated for patients and used under appropriate clinical care. The healthcare provider education component of the new IR-opioid REMS is mandatory. Documentation of program completion and knowledge assessment of the education are also mandatory. Providing continuing medical education credits for the REMS education is voluntary. The goal is to reduce overall opioid exposure by ensuring prescribers are properly informed about appropriate prescribing recommendations, understand how to identify the risk of abuse by individual patients and know how to get addicted patients into treatment.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Extending REMS to IR-opioid manufacturers will significantly increase the total number of covered opioids. After the requirement goes into effect, 277 more opioids will be subject to REMS. Implementation may take about a year to complete.

Other Actions in the Fight to Deter Opioid Abuse
The FDA is seeking public input relevant to its newly established Opioid Policy Steering Committee as it considers how its authority can or should be used to address the nation’s opioid abuse crisis. Comments must be submitted by Dec. 28, 2017.

Pages: 1 2 | Single Page

Filed Under: Analgesics, Drug Updates Tagged With: FDA, opioid, Opioid abuse, REMS, U.S. Food and Drug Administration (FDA)

You Might Also Like:
  • FDA Expands Safety Measures for Immediate Release Opioids
  • Makers of Fast-Acting Opioids Will Have to Pay for Training—FDA
  • FDA Panel Backs Teva’s Abuse-Resistant Opioid Painkiller
  • Most Seniors Won’t Abuse Opioids After Surgery

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.